Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | Q9HBH1 | 1/20 | 0.32 | |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2046468 | 1.00 | TSHR (0.33) | TSHRLMNACYP3A4NFKB1ADRA1A | |
| SCHEMBL1995258 | 0.86 | MMP1 (0.33) | TSHRLMNACYP3A4NFKB1ADRA1A | |
| SCHEMBL730936 | 0.86 | MMP1 (0.33) | TSHRLMNACYP3A4NFKB1ADRA1A | |
| SCHEMBL3513026 | 0.85 | TYR (0.37) | TSHRLMNACYP3A4NFKB1ADRA1A | |
| SCHEMBL8249267 | 0.84 | TSHR (0.33) | TSHRLMNACYP3A4NFKB1ADRA1A | |
| SCHEMBL731309 | 0.82 | PDF (0.34) | ||
| SCHEMBL1983553 | 0.82 | PDF (0.34) | ||
| SCHEMBL2049299 | 0.82 | CASP1 (0.39) | — | |
| SCHEMBL731986 | 0.82 | CASP1 (0.39) | — | |
| SCHEMBL6887447 | 0.81 | TSHR (0.34) | TSHRLMNACYP3A4NFKB1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086982-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9738661-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20150266897-A1 | HCV NS3 Protease Inhibitors | MSD ITALIA S.R.L. (IT) | 2015-09-24 | — | — | US | disclosed |
| EP-2076278-B1 | Macrocyclic HCV NS3 protease inhibitors | MERCK SHARP & DOHME (US) | 2015-05-06 | — | — | EP | disclosed |
| US-8962810-B2 | Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof | AB Pharma Ltd. (CN) | 2015-02-24 | — | — | US | disclosed |
| EP-2079479-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-11-26 | — | — | EP | disclosed |
| US-20140205567-A1 | Macrocyclic Heterocyclic Compound for Inhibiting Hepatitis C Virus and Preparation and Use Thereof | AB Pharma Ltd. (CN) | 2014-07-24 | — | — | US | disclosed |
| EP-1910404-B9 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-1910404-B9 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8637449-B2 | Processes for preparing protease inhibitors of hepatitis C virus | MERCK SHARP & DOHME CORP. (US) | 2014-01-28 | — | — | US | disclosed |
| WO-2008051477-A2 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| EP-1910404-A1 | HCV NS3 PROTEASE INHIBITORS | Merck & Co., Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007015787-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007015787-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007015855-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007015855-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007016441-A1 | MACROCYCLIC PEPTIDES AS HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027071-A1 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME LLC | 2007-02-01 | — | — | US | disclosed |
| US-20070027071-A1 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME LLC | 2007-02-01 | — | — | US | disclosed |
| US-20070027071-A1 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME LLC | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027071-A1 | HCV NS3 protease inhibitors | HAVCR2, GTF3C3, CTSC | TSHR 4610/4885LMNA 3730/4885CYP3A4 154/4885 |
| US-20140205567-A1 | Macrocyclic Heterocyclic Compound for Inhibiting Hepatitis C Virus and Preparation and Use Thereof | HAVCR2, ZC3HAV1, HCCS | TSHR 4104/4885LMNA 2939/4885CYP3A4 43/4885 |
| US-20150266897-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | TSHR 4610/4885LMNA 3730/4885CYP3A4 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.